andecaliximab + S-1 + oxaliplatin

**andecaliximab + S-1 + oxaliplatin** is a combination regimen under investigation for the first-line treatment of **HER2-negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma**[1]. - **Andecaliximab** is a recombinant chimeric immunoglobulin G4 monoclonal antibody that selectively inhibits matrix metalloproteinase 9 (MMP9), a zinc-dependent protease involved in tumor growth, metastasis, angiogenesis, and modulation of the immune microenvironment[1][2][4]. By blocking MMP9, andecaliximab may enhance chemotherapy efficacy and reduce immune suppression in the tumor stroma[1][2][3]. - **S-1** is an oral fluoropyrimidine derivative, combining tegafur (a prodrug of 5-fluorouracil), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (which reduces GI toxicity). It acts as a **pyrimidine analog antimetabolite**, inhibiting thymidylate synthase and DNA synthesis. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA replication and transcription, leading to cell death. The combined regimen is being explored for synergistic efficacy in gastric cancer and is associated with manageable safety and promising clinical activity (objective response rate ~73%, median progression-free survival ~11.9 months)[1]. Developers of andecaliximab include **Gilead Sciences**[2]. S-1 was developed by **Taiho Pharmaceutical**; oxaliplatin was discovered by **Debiopharm** and licensed/manufactured by companies including **Sanofi**.

Other names

ADX + S-1 + oxaliplatin